↓ Skip to main content

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis

Overview of attention for article published in BMC Cancer, August 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Published in
BMC Cancer, August 2016
DOI 10.1186/s12885-016-2618-1
Pubmed ID
Authors

D. Katz, Y. Azraq, F. Eleyan, S. Gill, T. Peretz, O. Merimsky

Abstract

To explore the activity of pazopanib (P) + sirolimus (S) in patients who progressed after previous clinical benefit on pazopanib. Eight patients with progressing metastatic high grade soft tissue sarcoma (STS) whose disease advanced on P following a response duration of at least 4 months were offered re-challenge of P supplemented by off-label S and a single patient with progressing metastatic chondrosarcoma was offered the combination as compassionate treatment. Patients were treated in two centers: Hadassah Medical Center and Tel Aviv Medical Center. Patients received oral P 200-600 mg once a day supplemented by S 3-4 mg taken separately, 12 h after the P dose. Patients received treatment from December 2012 to February 2016. Four progressed on the combination and their treatment was terminated. Two patients were undergoing treatment when data was summarized. Best Response Evaluation Criteria in Solid Tumour (RECIST) responses were: one partial response (PR), four stable disease (SD), and four progressive disease (PD), corresponding to five PR and four PD on the Choi criteria. Median progression free survival was 5.5 months (range 4-17). Our series showed that the combination of P + S has activity in STS patients selected by previous response to P and in a patient with chondrosarcoma, suggesting this can serve as a mechanism to reverse resistance to P and extend the chemotherapy-free window.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 6%
Unknown 17 94%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 17%
Student > Doctoral Student 3 17%
Researcher 3 17%
Student > Master 3 17%
Student > Ph. D. Student 1 6%
Other 3 17%
Unknown 2 11%
Readers by discipline Count As %
Medicine and Dentistry 7 39%
Agricultural and Biological Sciences 3 17%
Biochemistry, Genetics and Molecular Biology 2 11%
Psychology 2 11%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 3 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2016.
All research outputs
#7,089,787
of 8,192,854 outputs
Outputs from BMC Cancer
#2,802
of 3,461 outputs
Outputs of similar age
#217,303
of 257,284 outputs
Outputs of similar age from BMC Cancer
#186
of 261 outputs
Altmetric has tracked 8,192,854 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,461 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,284 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 261 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.